Mike Nally is the Chief Executive Officer of Generate:Biomedicines and is a CEO-Partner at Flagship Pioneering. With a deep commitment to innovation and patient care, Mike's expertise in leading global organizations has been instrumental in the company's efforts to make protein therapeutics programmable. Since his appointment in 2021, Mike has been a driving force behind several key initiatives that have significantly bolstered Generate:Biomedicines' position as the leader in Generative Biology®. Under his leadership, the company successfully completed its Series B and C financing rounds and has raised more than $750 million since inception. These funding milestones have enabled the advancement of Generate:Biomedicines’ pioneering work in generative AI and a robust pipeline of protein therapeutics with two clinical assets and more than 15 preclinical candidates. Mike has also been instrumental in forging significant partnerships with leading institutions, laying a strong foundation for future advancement. For example, the company announced a collaboration with Amgen in 2022, which was expanded in early 2024. Later that year, the company entered into a multi-target collaboration with Novartis, valued at more than $1 billion. Additionally, in 2023, the Company announced strategic collaborations with the MD Anderson Cancer Center and Roswell Park Comprehensive Cancer Center, which aim to harness their respective strengths in specialized medical research and treatment modalities to deliver novel therapeutics in oncology and CAR-T cells respectively. Before joining Generate:Biomedicines, Mike held several key leadership positions at Merck & Co., Inc. As Chief Marketing Officer, he was responsible for the Global Marketing and Brand Strategy of a diverse portfolio encompassing innovative medicines and vaccines, generating over $40 billion in revenue. His previous roles at Merck & Co. include serving as President of Global Vaccines and managing the company's operations in Sweden and the UK. In addition to his executive role at Generate:Biomedicines, Mike continues to contribute his expertise as a board member for Flagship's Harbinger Health and PPG Industries. At PPG Industries, he is an active member of the Audit and Sustainability and Innovation Committees. Mike holds an MBA from Harvard Business School, a degree in Accounting and Finance from the London School of Economics, and a BA in Economics from Middlebury College.